Acadia PharmaceuticalsACAD
Market Cap: $2.74B
About: Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Employees: 690
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
120% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $6.12M
35% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 80
0% more funds holding
Funds holding: 264 [Q1] → 264 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q1] → 5 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 41
0.82% less ownership
Funds ownership: 98.24% [Q1] → 97.42% (-0.82%) [Q2]
13% less capital invested
Capital invested by funds: $2.99B [Q1] → $2.61B (-$377M) [Q2]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
10 analyst ratings
Citigroup David Hoang 48% 1-year accuracy 10 / 21 met price target | 39%upside $23 | Buy Maintained | 8 Aug 2024 |
UBS Ashwani Verma 47% 1-year accuracy 8 / 17 met price target | 39%upside $23 | Buy Maintained | 8 Aug 2024 |
HC Wainwright & Co. Andrew Fein 45% 1-year accuracy 75 / 165 met price target | 63%upside $27 | Buy Reiterated | 8 Aug 2024 |
Needham Ami Fadia 53% 1-year accuracy 65 / 122 met price target | 69%upside $28 | Buy Maintained | 7 Aug 2024 |
Cantor Fitzgerald Charles Duncan 46% 1-year accuracy 33 / 72 met price target | 69%upside $28 | Overweight Maintained | 7 Aug 2024 |
Financial journalist opinion
Based on 4 articles about ACAD published over the past 30 days